报价延迟最少15分钟:2026/03/21 01:31 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.4 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.49/-0.92
|
|
企业价值
1.19B
|
| 资产负债 |
|
每股账面净值
3.19
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
75.13M
|
|
每股收益
0.17
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications. ABCL635, ABCL386, ABCL575, and ABCL635. |
